抗DLL3抗体とその製造方法、その薬物複合体及び使用

JP7892050B2Active Publication Date: 2026-07-17SHANGHAI FUDAN ZHANGJIANG BIO PHARMA
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SHANGHAI FUDAN ZHANGJIANG BIO PHARMA
Filing Date
2022-07-29
Publication Date
2026-07-17

Smart Images

  • Figure 0007892050000113
    Figure 0007892050000113
  • Figure 0007892050000114
    Figure 0007892050000114
  • Figure 0007892050000115
    Figure 0007892050000115
Patent Text Reader

Abstract

The present invention discloses an anti-DLL3 antibody and its preparation method, drug conjugate and use thereof. The anti-DLL3 antibody of the present invention has good internalization activity, better binding activity to human DLL3 protein, and strong affinity at the protein level. The antibody-drug conjugate targeting DLL3 of the present invention has good druggability, biological activity, and antitumor activity in vivo and in vitro, and can realize the use of cytotoxic agents in the treatment of patients with tumors with neuroendocrine characteristics, including SCLC.
Need to check novelty before this filing date? Find Prior Art